Diabetes and Metabolism Journal

Korean Diabetes Association (대한당뇨병학회)
권호 표지
DOI QR코드

DOI QR Code

Latent Autoimmune Diabetes in Adults: A Review on Clinical Implications and Management

  • Pieralice, Silvia (Department of Endocrinology and Diabetes, University Campus Bio-Medico) ;
  • Pozzilli, Paolo (Department of Endocrinology and Diabetes, University Campus Bio-Medico)
  • Received : 2018.09.20
  • Accepted : 2018.11.14
  • Published : 2018.12.30
⟨ Previous Next ⟩

Abstract

Latent autoimmune diabetes in adults (LADA) is a heterogeneous disease characterized by a less intensive autoimmune process and a broad clinical phenotype compared to classical type 1 diabetes mellitus (T1DM), sharing features with both type 2 diabetes mellitus (T2DM) and T1DM. Since patients affected by LADA are initially insulin independent and recognizable only by testing for islet-cell autoantibodies, it could be difficult to identify LADA in clinical setting and a high misdiagnosis rate still remains among patients with T2DM. Ideally, islet-cell autoantibodies screening should be performed in subjects with newly diagnosed T2DM, ensuring a closer monitoring of those resulted positive and avoiding treatment of hyperglycaemia which might increase the rate of ${\beta}-cells$ loss. Thus, since the autoimmune process in LADA seems to be slower than in classical T1DM, there is a wider window for new therapeutic interventions that may slow down ${\beta}-cell$ failure. This review summarizes the current understanding of LADA, by evaluating data from most recent studies, the actual gaps in diagnosis and management. Finally, we critically highlight and discuss novel findings and future perspectives on the therapeutic approach in LADA.

Keywords

References

  1. Bluestone JA, Herold K, Eisenbarth G. Genetics, pathogenesis and clinical interventions in type 1 diabetes. Nature 2010;464: 1293-300. https://doi.org/10.1038/nature08933
  2. Mishra R, Hodge KM, Cousminer DL, Leslie RD, Grant SFA. A global perspective of latent autoimmune diabetes in adults. Trends Endocrinol Metab 2018;29:638-50. https://doi.org/10.1016/j.tem.2018.07.001
  3. Tuomi T, Groop LC, Zimmet PZ, Rowley MJ, Knowles W, Mackay IR. Antibodies to glutamic acid decarboxylase reveal latent autoimmune diabetes mellitus in adults with a non-insulin-dependent onset of disease. Diabetes 1993;42:359-62. https://doi.org/10.2337/diab.42.2.359
  4. Hawa MI, Kolb H, Schloot N, Beyan H, Paschou SA, Buzzetti R, Mauricio D, De Leiva A, Yderstraede K, Beck-Neilsen H, Tuomilehto J, Sarti C, Thivolet C, Hadden D, Hunter S, Schernthaner G, Scherbaum WA, Williams R, Brophy S, Pozzilli P, Leslie RD; Action LADA consortium. Adult-onset autoimmune diabetes in Europe is prevalent with a broad clinical phenotype: Action LADA 7. Diabetes Care 2013;36:908-13. https://doi.org/10.2337/dc12-0931
  5. Maddaloni E, Lessan N, Al Tikriti A, Buzzetti R, Pozzilli P, Barakat MT. Latent autoimmune diabetes in adults in the United Arab Emirates: clinical features and factors related to insulin-requirement. PLoS One 2015;10:e0131837. https://doi.org/10.1371/journal.pone.0131837
  6. Pozzilli P, Di Mario U. Autoimmune diabetes not requiring insulin at diagnosis (latent autoimmune diabetes of the adult): definition, characterization, and potential prevention. Diabetes Care 2001;24:1460-7. https://doi.org/10.2337/diacare.24.8.1460
  7. American Diabetes Association. (2) Classification and diagnosis of diabetes. Diabetes Care 2015;38 Suppl:S8-16.
  8. Leslie RD, Williams R, Pozzilli P. Clinical review: type 1 diabetes and latent autoimmune diabetes in adults: one end of the rainbow. J Clin Endocrinol Metab 2006;91:1654-9. https://doi.org/10.1210/jc.2005-1623
  9. Kobayashi T, Nakanishi K, Murase T, Kosaka K. Small doses of subcutaneous insulin as a strategy for preventing slowly progressive beta-cell failure in islet cell antibody-positive patients with clinical features of NIDDM. Diabetes 1996;45:622-6. https://doi.org/10.2337/diab.45.5.622
  10. Yasui J, Kawasaki E, Tanaka S, Awata T, Ikegami H, Imagawa A, Uchigata Y, Osawa H, Kajio H, Kawabata Y, Shimada A, Takahashi K, Yasuda K, Yasuda H, Hanafusa T, Kobayashi T; Japan Diabetes Society Committee on Type 1 Diabetes Mellitus Research. Clinical and genetic characteristics of non-insulin-requiring glutamic acid decarboxylase (GAD) autoantibody-positive diabetes: a nationwide survey in Japan. PLoS One 2016;11:e0155643. https://doi.org/10.1371/journal.pone.0155643
  11. Sabbah E, Savola K, Ebeling T, Kulmala P, Vahasalo P, Ilonen J, Salmela PI, Knip M. Genetic, autoimmune, and clinical characteristics of childhood- and adult-onset type 1 diabetes. Diabetes Care 2000;23:1326-32. https://doi.org/10.2337/diacare.23.9.1326
  12. Howson JM, Rosinger S, Smyth DJ, Boehm BO; ADBW-END Study Group, Todd JA. Genetic analysis of adult-onset autoimmune diabetes. Diabetes 2011;60:2645-53. https://doi.org/10.2337/db11-0364
  13. Hernandez M, Mollo A, Marsal JR, Esquerda A, Capel I, Puig-Domingo M, Pozzilli P, de Leiva A, Mauricio D; Action LADA consortium. Insulin secretion in patients with latent autoimmune diabetes (LADA): half way between type 1 and type 2 diabetes: action LADA 9. BMC Endocr Disord 2015;15:1. https://doi.org/10.1186/1472-6823-15-1
  14. Park Y, Wintergerst KA, Zhou Z. Clinical heterogeneity of type 1 diabetes (T1D) found in Asia. Diabetes Metab Res Rev 2017; 33:e2907. https://doi.org/10.1002/dmrr.2907
  15. Buzzetti R, Zampetti S, Maddaloni E. Adult-onset autoimmune diabetes: current knowledge and implications for management. Nat Rev Endocrinol 2017;13:674-86. https://doi.org/10.1038/nrendo.2017.99
  16. Fourlanos S, Dotta F, Greenbaum CJ, Palmer JP, Rolandsson O, Colman PG, Harrison LC. Latent autoimmune diabetes in adults (LADA) should be less latent. Diabetologia 2005;48: 2206-12. https://doi.org/10.1007/s00125-005-1960-7
  17. Maioli M, Pes GM, Delitala G, Puddu L, Falorni A, Tolu F, Lampis R, Orru V, Secchi G, Cicalo AM, Floris R, Madau GF, Pilosu RM, Whalen M, Cucca F. Number of autoantibodies and HLA genotype, more than high titers of glutamic acid decarboxylase autoantibodies, predict insulin dependence in latent autoimmune diabetes of adults. Eur J Endocrinol 2010; 163:541-9. https://doi.org/10.1530/EJE-10-0427
  18. Roh MO, Jung CH, Kim BY, Mok JO, Kim CH. The prevalence and characteristics of latent autoimmune diabetes in adults (LADA) and its relation with chronic complications in a clinical department of a university hospital in Korea. Acta Diabetol 2013;50:129-34. https://doi.org/10.1007/s00592-010-0228-y
  19. Naik RG, Brooks-Worrell BM, Palmer JP. Latent autoimmune diabetes in adults. J Clin Endocrinol Metab 2009;94:4635-44. https://doi.org/10.1210/jc.2009-1120
  20. Buzzetti R, Di Pietro S, Giaccari A, Petrone A, Locatelli M, Suraci C, Capizzi M, Arpi ML, Bazzigaluppi E, Dotta F, Bosi E; Non Insulin Requiring Autoimmune Diabetes Study Group. High titer of autoantibodies to GAD identifies a specific phenotype of adult-onset autoimmune diabetes. Diabetes Care 2007;30:932-8. https://doi.org/10.2337/dc06-1696
  21. Radtke MA, Midthjell K, Nilsen TI, Grill V. Heterogeneity of patients with latent autoimmune diabetes in adults: linkage to autoimmunity is apparent only in those with perceived need for insulin treatment: results from the Nord-Trondelag Health (HUNT) study. Diabetes Care 2009;32:245-50. https://doi.org/10.2337/dc08-1468
  22. Park Y, Hong S, Park L, Woo J, Baik S, Nam M, Lee K, Kim Y; KNDP collaboratory Group. LADA prevalence estimation and insulin dependency during follow-up. Diabetes Metab Res Rev 2011;27:975-9. https://doi.org/10.1002/dmrr.1278
  23. Bruno G, Runzo C, Cavallo-Perin P, Merletti F, Rivetti M, Pinach S, Novelli G, Trovati M, Cerutti F, Pagano G; Piedmont Study Group for Diabetes Epidemiology. Incidence of type 1 and type 2 diabetes in adults aged 30-49 years: the population-based registry in the province of Turin, Italy. Diabetes Care 2005;28:2613-9. https://doi.org/10.2337/diacare.28.11.2613
  24. Rawshani A, Landin-Olsson M, Svensson AM, Nystrom L, Arnqvist HJ, Bolinder J, Gudbjornsdottir S. The incidence of diabetes among 0-34 year olds in Sweden: new data and better methods. Diabetologia 2014;57:1375-81. https://doi.org/10.1007/s00125-014-3225-9
  25. Turner R, Stratton I, Horton V, Manley S, Zimmet P, Mackay IR, Shattock M, Bottazzo GF, Holman R. UKPDS 25: autoantibodies to islet-cell cytoplasm and glutamic acid decarboxylase for prediction of insulin requirement in type 2 diabetes. UK Prospective Diabetes Study Group. Lancet 1997;350:1288-93. https://doi.org/10.1016/S0140-6736(97)03062-6
  26. Tuomi T, Carlsson A, Li H, Isomaa B, Miettinen A, Nilsson A, Nissen M, Ehrnstrom BO, Forsen B, Snickars B, Lahti K, Forsblom C, Saloranta C, Taskinen MR, Groop LC. Clinical and genetic characteristics of type 2 diabetes with and without GAD antibodies. Diabetes 1999;48:150-7. https://doi.org/10.2337/diabetes.48.1.150
  27. Takeda H, Kawasaki E, Shimizu I, Konoue E, Fujiyama M, Murao S, Tanaka K, Mori K, Tarumi Y, Seto I, Fujii Y, Kato K, Kondo S, Takada Y, Kitsuki N, Kaino Y, Kida K, Hashimoto N, Yamane Y, Yamawaki T, Onuma H, Nishimiya T, Osawa H, Saito Y, Makino H; Ehime Study. Clinical, autoimmune, and genetic characteristics of adult-onset diabetic patients with GAD autoantibodies in Japan (Ehime Study). Diabetes Care 2002;25:995-1001. https://doi.org/10.2337/diacare.25.6.995
  28. Zinman B, Kahn SE, Haffner SM, O'Neill MC, Heise MA, Freed MI; ADOPT Study Group. Phenotypic characteristics of GAD antibody-positive recently diagnosed patients with type 2 diabetes in North America and Europe. Diabetes 2004;53:3193-200. https://doi.org/10.2337/diabetes.53.12.3193
  29. Qi X, Sun J, Wang J, Wang PP, Xu Z, Murphy M, Jia J, Wang J, Xie Y, Xu W. Prevalence and correlates of latent autoimmune diabetes in adults in Tianjin, China: a population-based cross-sectional study. Diabetes Care 2011;34:66-70. https://doi.org/10.2337/dc10-0488
  30. Lee SH, Kwon HS, Yoo SJ, Ahn YB, Yoon KH, Cha BY, Lee KW, Son HY. Identifying latent autoimmune diabetes in adults in Korea: the role of C-peptide and metabolic syndrome. Diabetes Res Clin Pract 2009;83:e62-5. https://doi.org/10.1016/j.diabres.2008.11.031
  31. Britten AC, Jones K, Torn C, Hillman M, Ekholm B, Kumar S, Barnett AH, Kelly MA. Latent autoimmune diabetes in adults in a South Asian population of the U.K. Diabetes Care 2007;30: 3088-90. https://doi.org/10.2337/dc07-0896
  32. Sachan A, Zaidi G, Sahu RP, Agrawal S, Colman PG, Bhatia E. Low prevalence of latent autoimmune diabetes in adults in northern India. Diabet Med 2015;32:810-3. https://doi.org/10.1111/dme.12644
  33. Zhou Z, Xiang Y, Ji L, Jia W, Ning G, Huang G, Yang L, Lin J, Liu Z, Hagopian WA, Leslie RD; LADA China Study Group. Frequency, immunogenetics, and clinical characteristics of latent autoimmune diabetes in China (LADA China study): a nationwide, multicenter, clinic-based cross-sectional study. Diabetes 2013;62:543-50. https://doi.org/10.2337/db12-0207
  34. Haller K, Kisand K, Pisarev H, Salur L, Laisk T, Nemvalts V, Uibo R. Insulin gene VNTR, CTLA-4 +49A/G and HLA-DQB1 alleles distinguish latent autoimmune diabetes in adults from type 1 diabetes and from type 2 diabetes group. Tissue Antigens 2007;69:121-7. https://doi.org/10.1111/j.1399-0039.2006.00745.x
  35. Grant SF, Thorleifsson G, Reynisdottir I, Benediktsson R, Manolescu A, Sainz J, Helgason A, Stefansson H, Emilsson V, Helgadottir A, Styrkarsdottir U, Magnusson KP, Walters GB, Palsdottir E, Jonsdottir T, Gudmundsdottir T, Gylfason A, Saemundsdottir J, Wilensky RL, Reilly MP, Rader DJ, Bagger Y, Christiansen C, Gudnason V, Sigurdsson G, Thorsteinsdottir U, Gulcher JR, Kong A, Stefansson K. Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes. Nat Genet 2006;38:320-3. https://doi.org/10.1038/ng1732
  36. Field SF, Howson JM, Smyth DJ, Walker NM, Dunger DB, Todd JA. Analysis of the type 2 diabetes gene, TCF7L2, in 13,795 type 1 diabetes cases and control subjects. Diabetologia 2007;50:212-3.
  37. Qu HQ, Grant SF, Bradfield JP, Kim C, Frackelton E, Hakonarson H, Polychronakos C. Association analysis of type 2 diabetes Loci in type 1 diabetes. Diabetes 2008;57:1983-6. https://doi.org/10.2337/db08-0270
  38. Desai M, Zeggini E, Horton VA, Owen KR, Hattersley AT, Levy JC, Walker M, Gillespie KM, Bingley PJ, Hitman GA, Holman RR, McCarthy MI, Clark A. An association analysis of the HLA gene region in latent autoimmune diabetes in adults. Diabetologia 2007;50:68-73.
  39. Andersen MK, Lundgren V, Turunen JA, Forsblom C, Isomaa B, Groop PH, Groop L, Tuomi T. Latent autoimmune diabetes in adults differs genetically from classical type 1 diabetes diagnosed after the age of 35 years. Diabetes Care 2010;33:2062-4. https://doi.org/10.2337/dc09-2188
  40. Barinas-Mitchell E, Pietropaolo S, Zhang YJ, Henderson T, Trucco M, Kuller LH, Pietropaolo M. Islet cell autoimmunity in a triethnic adult population of the Third National Health and Nutrition Examination Survey. Diabetes 2004;53:1293-302. https://doi.org/10.2337/diabetes.53.5.1293
  41. Yang Z, Wang K, Li T, Sun W, Li Y, Chang YF, Dorman JS, LaPorte RE. Childhood diabetes in China. Enormous variation by place and ethnic group. Diabetes Care 1998;21:525-9. https://doi.org/10.2337/diacare.21.4.525
  42. Barker A, Lauria A, Schloot N, Hosszufalusi N, Ludvigsson J, Mathieu C, Mauricio D, Nordwall M, Van der Schueren B, Mandrup-Poulsen T, Scherbaum WA, Weets I, Gorus FK, Wareham N, Leslie RD, Pozzilli P. Age-dependent decline of ${\beta}$-cell function in type 1 diabetes after diagnosis: a multi-centre longitudinal study. Diabetes Obes Metab 2014;16:262-7. https://doi.org/10.1111/dom.12216
  43. Lampasona V, Petrone A, Tiberti C, Capizzi M, Spoletini M, di Pietro S, Songini M, Bonicchio S, Giorgino F, Bonifacio E, Bosi E, Buzzetti R; Non Insulin Requiring Autoimmune Diabetes (NIRAD) Study Group. Zinc transporter 8 antibodies complement GAD and IA-2 antibodies in the identification and characterization of adult-onset autoimmune diabetes: Non Insulin Requiring Autoimmune Diabetes (NIRAD) 4. Diabetes Care 2010;33:104-8. https://doi.org/10.2337/dc08-2305
  44. Tiberti C, Giordano C, Locatelli M, Bosi E, Bottazzo GF, Buzzetti R, Cucinotta D, Galluzzo A, Falorni A, Dotta F. Identification of tyrosine phosphatase 2(256-760) construct as a new, sensitive marker for the detection of islet autoimmunity in type 2 diabetic patients: the non-insulin requiring autoimmune diabetes (NIRAD) study 2. Diabetes 2008;57:1276-83. https://doi.org/10.2337/db07-0874
  45. Buzzetti R, Spoletini M, Zampetti S, Campagna G, Marandola L, Panimolle F, Dotta F, Tiberti C; NIRAD Study Group (NIRAD 8). Tyrosine phosphatase-related islet antigen 2(256-760) autoantibodies, the only marker of islet autoimmunity that increases by increasing the degree of BMI in obese subjects with type 2 diabetes. Diabetes Care 2015;38:513-20. https://doi.org/10.2337/dc14-1638
  46. Hawa MI, Thivolet C, Mauricio D, Alemanno I, Cipponeri E, Collier D, Hunter S, Buzzetti R, de Leiva A, Pozzilli P, Leslie RD; Action LADA Group. Metabolic syndrome and autoimmune diabetes: action LADA 3. Diabetes Care 2009;32:160-4. https://doi.org/10.2337/dc08-1419
  47. Hjort R, Ahlqvist E, Carlsson PO, Grill V, Groop L, Martinell M, Rasouli B, Rosengren A, Tuomi T, Asvold BO, Carlsson S. Overweight, obesity and the risk of LADA: results from a Swedish case-control study and the Norwegian HUNT Study. Diabetologia 2018;61:1333-43. https://doi.org/10.1007/s00125-018-4596-0
  48. Leslie RD, Kolb H, Schloot NC, Buzzetti R, Mauricio D, De Leiva A, Yderstraede K, Sarti C, Thivolet C, Hadden D, Hunter S, Schernthaner G, Scherbaum W, Williams R, Pozzilli P. Diabetes classification: grey zones, sound and smoke: Action LADA 1. Diabetes Metab Res Rev 2008;24:511-9. https://doi.org/10.1002/dmrr.877
  49. Zampetti S, Capizzi M, Spoletini M, Campagna G, Leto G, Cipolloni L, Tiberti C, Bosi E, Falorni A, Buzzetti R; NIRAD Study Group. GADA titer-related risk for organ-specific autoimmunity in LADA subjects subdivided according to gender (NIRAD study 6). J Clin Endocrinol Metab 2012;97:3759-65. https://doi.org/10.1210/jc.2012-2037
  50. Genovese S, Bazzigaluppi E, Goncalves D, Ciucci A, Cavallo MG, Purrello F, Anello M, Rotella CM, Bardini G, Vaccaro O, Riccardi G, Travaglini P, Morenghi E, Bosi E, Pozzilli P. Clinical phenotype and beta-cell autoimmunity in Italian patients with adult-onset diabetes. Eur J Endocrinol 2006;154:441-7. https://doi.org/10.1530/eje.1.02115
  51. Desai M, Cull CA, Horton VA, Christie MR, Bonifacio E, Lampasona V, Bingley PJ, Levy JC, Mackay IR, Zimmet P, Holman RR, Clark A. GAD autoantibodies and epitope reactivities persist after diagnosis in latent autoimmune diabetes in adults but do not predict disease progression: UKPDS 77. Diabetologia 2007;50:2052-60. https://doi.org/10.1007/s00125-007-0745-6
  52. Fourlanos S, Perry C, Stein MS, Stankovich J, Harrison LC, Colman PG. A clinical screening tool identifies autoimmune diabetes in adults. Diabetes Care 2006;29:970-5. https://doi.org/10.2337/dc05-2101
  53. Monge L, Bruno G, Pinach S, Grassi G, Maghenzani G, Dani F, Pagano G. A clinically orientated approach increases the efficiency of screening for latent autoimmune diabetes in adults (LADA) in a large clinic-based cohort of patients with diabetes onset over 50 years. Diabet Med 2004;21:456-9. https://doi.org/10.1111/j.1464-5491.2004.01177.x
  54. Davis AK, DuBose SN, Haller MJ, Miller KM, DiMeglio LA, Bethin KE, Goland RS, Greenberg EM, Liljenquist DR, Ahmann AJ, Marcovina SM, Peters AL, Beck RW, Greenbaum CJ; T1D Exchange Clinic Network. Prevalence of detectable C-Peptide according to age at diagnosis and duration of type 1 diabetes. Diabetes Care 2015;38:476-81. https://doi.org/10.2337/dc14-1952
  55. Pipi E, Marketou M, Tsirogianni A. Distinct clinical and laboratory characteristics of latent autoimmune diabetes in adults in relation to type 1 and type 2 diabetes mellitus. World J Diabetes 2014;5:505-10. https://doi.org/10.4239/wjd.v5.i4.505
  56. Bell DS, Ovalle F. The role of C-peptide levels in screening for latent autoimmune diabetes in adults. Am J Ther 2004;11:308-11. https://doi.org/10.1097/01.mjt.0000102372.28723.2b
  57. Zampetti S, Campagna G, Tiberti C, Songini M, Arpi ML, De Simone G, Cossu E, Cocco L, Osborn J, Bosi E, Giorgino F, Spoletini M, Buzzetti R; NIRAD Study Group. High GADA titer increases the risk of insulin requirement in LADA patients: a 7-year follow-up (NIRAD study 7). Eur J Endocrinol 2014; 171:697-704. https://doi.org/10.1530/EJE-14-0342
  58. Argoud GM, Schade DS, Eaton RP. Insulin suppresses its own secretion in vivo. Diabetes 1987;36:959-62. https://doi.org/10.2337/diab.36.8.959
  59. Jansen A, Rosmalen JG, Homo-Delarche F, Dardenne M, Drexhage HA. Effect of prophylactic insulin treatment on the number of ER-MP23+ macrophages in the pancreas of NOD mice. Is the prevention of diabetes based on beta-cell rest? J Autoimmun 1996;9:341-8. https://doi.org/10.1006/jaut.1996.0046
  60. Steffes MW, Sibley S, Jackson M, Thomas W. Beta-cell function and the development of diabetes-related complications in the diabetes control and complications trial. Diabetes Care 2003; 26:832-6. https://doi.org/10.2337/diacare.26.3.832
  61. Thunander M, Thorgeirsson H, Torn C, Petersson C, Landin-Olsson M. ${\beta}$-Cell function and metabolic control in latent autoimmune diabetes in adults with early insulin versus conventional treatment: a 3-year follow-up. Eur J Endocrinol 2011; 164:239-45. https://doi.org/10.1530/EJE-10-0901
  62. Fuchtenbusch M, Kredel K, Bonifacio E, Schnell O, Ziegler AG. Exposure to exogenous insulin promotes IgG1 and the T-helper 2-associated IgG4 responses to insulin but not to other islet autoantigens. Diabetes 2000;49:918-25. https://doi.org/10.2337/diabetes.49.6.918
  63. Tiittanen M, Huupponen JT, Knip M, Vaarala O. Insulin treatment in patients with type 1 diabetes induces upregulation of regulatory T-cell markers in peripheral blood mononuclear cells stimulated with insulin in vitro. Diabetes 2006;55:3446-54. https://doi.org/10.2337/db06-0132
  64. Schloot N, Eisenbarth GS. Isohormonal therapy of endocrine autoimmunity. Immunol Today 1995;16:289-94. https://doi.org/10.1016/0167-5699(95)80183-9
  65. Brophy S, Davies H, Mannan S, Brunt H, Williams R. Interventions for latent autoimmune diabetes (LADA) in adults. Cochrane Database Syst Rev 2011;9:CD006165.
  66. Maruyama T, Tanaka S, Shimada A, Funae O, Kasuga A, Kanatsuka A, Takei I, Yamada S, Harii N, Shimura H, Kobayashi T. Insulin intervention in slowly progressive insulin-dependent (type 1) diabetes mellitus. J Clin Endocrinol Metab 2008; 93:2115-21. https://doi.org/10.1210/jc.2007-2267
  67. George P, McCrimmon RJ. Potential role of non-insulin adjunct therapy in type 1 diabetes. Diabet Med 2013;30:179-88. https://doi.org/10.1111/j.1464-5491.2012.03744.x
  68. Zhou Z, Li X, Huang G, Peng J, Yang L, Yan X, Wang J. Rosiglitazone combined with insulin preserves islet beta cell function in adult-onset latent autoimmune diabetes (LADA). Diabetes Metab Res Rev 2005;21:203-8. https://doi.org/10.1002/dmrr.503
  69. D'Alessio DA, Denney AM, Hermiller LM, Prigeon RL, Martin JM, Tharp WG, Saylan ML, He Y, Dunning BE, Foley JE, Pratley RE. Treatment with the dipeptidyl peptidase-4 inhibitor vildagliptin improves fasting islet-cell function in subjects with type 2 diabetes. J Clin Endocrinol Metab 2009;94:81-8. https://doi.org/10.1210/jc.2008-1135
  70. Foley JE, Bunck MC, Moller-Goede DL, Poelma M, Nijpels G, Eekhoff EM, Schweizer A, Heine RJ, Diamant M. Beta cell function following 1 year vildagliptin or placebo treatment and after 12 week washout in drug-naive patients with type 2 diabetes and mild hyperglycaemia: a randomised controlled trial. Diabetologia 2011;54:1985-91. https://doi.org/10.1007/s00125-011-2167-8
  71. Tian L, Gao J, Hao J, Zhang Y, Yi H, O'Brien TD, Sorenson R, Luo J, Guo Z. Reversal of new-onset diabetes through modulating inflammation and stimulating beta-cell replication in nonobese diabetic mice by a dipeptidyl peptidase IV inhibitor. Endocrinology 2010;151:3049-60. https://doi.org/10.1210/en.2010-0068
  72. Zhao Y, Yang L, Xiang Y, Liu L, Huang G, Long Z, Li X, Leslie RD, Wang X, Zhou Z. Dipeptidyl peptidase 4 inhibitor sitagliptin maintains ${\beta}$-cell function in patients with recent-onset latent autoimmune diabetes in adults: one year prospective study. J Clin Endocrinol Metab 2014;99:E876-80. https://doi.org/10.1210/jc.2013-3633
  73. Johansen OE, Boehm BO, Grill V, Torjesen PA, Bhattacharya S, Patel S, Wetzel K, Woerle HJ. C-peptide levels in latent autoimmune diabetes in adults treated with linagliptin versus glimepiride: exploratory results from a 2-year double-blind, randomized, controlled study. Diabetes Care 2014;37:e11-2. https://doi.org/10.2337/dc13-1523
  74. Buzzetti R, Pozzilli P, Frederich R, Iqbal N, Hirshberg B. Saxagliptin improves glycaemic control and C-peptide secretion in latent autoimmune diabetes in adults (LADA). Diabetes Metab Res Rev 2016;32:289-96. https://doi.org/10.1002/dmrr.2717
  75. Dejgaard TF, Frandsen CS, Hansen TS, Almdal T, Urhammer S, Pedersen-Bjergaard U, Jensen T, Jensen AK, Holst JJ, Tarnow L, Knop FK, Madsbad S, Andersen HU. Efficacy and safety of liraglutide for overweight adult patients with type 1 diabetes and insufficient glycaemic control (Lira-1): a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol 2016;4:221-32. https://doi.org/10.1016/S2213-8587(15)00436-2
  76. Pettus J, Hirsch I, Edelman S. GLP-1 agonists in type 1 diabetes. Clin Immunol 2013;149:317-23. https://doi.org/10.1016/j.clim.2013.04.006
  77. Pozzilli P, Leslie RD, Peters AL, Buzzetti R, Shankar SS, Milicevic Z, Pavo I, Lebrec J, Martin S, Schloot NC. Dulaglutide treatment results in effective glycaemic control in latent autoimmune diabetes in adults (LADA): a post-hoc analysis of the AWARD-2, -4 and -5 trials. Diabetes Obes Metab 2018;20: 1490-8. https://doi.org/10.1111/dom.13237
  78. Jones AG, McDonald TJ, Shields BM, Hill AV, Hyde CJ, Knight BA, Hattersley AT; PRIBA Study Group. Markers of ${\beta}$-cell failure predict poor glycemic response to GLP-1 receptor agonist therapy in type 2 diabetes. Diabetes Care 2016;39:250-7.
  79. Yang Z, Zhou Z, Li X, Huang G, Lin J. Rosiglitazone preserves islet beta-cell function of adult-onset latent autoimmune diabetes in 3 years follow-up study. Diabetes Res Clin Pract 2009; 83:54-60. https://doi.org/10.1016/j.diabres.2008.09.044

Cited by

  1. Autoimmunity in latent autoimmune diabetes in adults vol.6, pp.2, 2018, https://doi.org/10.3934/medsci.2019.2.132
  2. Subphänotypen des Diabetes vol.15, pp.4, 2019, https://doi.org/10.1007/s11428-019-0451-2
  3. The Influence of Type 2 Diabetes–Associated Factors on Type 1 Diabetes vol.42, pp.8, 2018, https://doi.org/10.2337/dc19-0102
  4. Latenter Autoimmundiabetes im Erwachsenen- und Kindesalter : LADA und LADY vol.16, pp.1, 2018, https://doi.org/10.1007/s11428-019-00556-z
  5. Uncommon Presentations of Diabetes: Zebras in the Herd vol.38, pp.1, 2018, https://doi.org/10.2337/cd19-0019
  6. The Differential Expression of Long Noncoding RNAs in Type 2 Diabetes Mellitus and Latent Autoimmune Diabetes in Adults vol.2020, pp.None, 2020, https://doi.org/10.1155/2020/9235329
  7. A convenient diagnostic tool for discriminating adult-onset glutamic acid decarboxylase antibody-positive autoimmune diabetes from type 2 diabetes: a retrospective study vol.8, pp.None, 2018, https://doi.org/10.7717/peerj.8610
  8. Therapeutic approaches for latent autoimmune diabetes in adults: One size does not fit all vol.12, pp.2, 2020, https://doi.org/10.1111/1753-0407.12982
  9. Case 6-2020: A 34-Year-Old Woman with Hyperglycemia vol.382, pp.8, 2020, https://doi.org/10.1056/nejmcpc1913475
  10. Grenzformen zwischen Typ-1- und Typ-2-Diabetes : Seminar / Diabetes vol.162, pp.11, 2018, https://doi.org/10.1007/s15006-020-0577-6
  11. Ketogenic Diet as a Trigger for Diabetic Ketoacidosis in a Misdiagnosis of Diabetes: A Case Report vol.38, pp.3, 2020, https://doi.org/10.2337/cd20-0001
  12. Correct Diabetes Diagnosis and Treatment Allows Sailor to Remain on Active Duty vol.185, pp.9, 2020, https://doi.org/10.1093/milmed/usaa012
  13. Dapagliflozin as an Adjunct Therapy to Insulin in Patients with Type 1 Diabetes Mellitus: Efficacy and Safety of this Combination vol.1, pp.1, 2018, https://doi.org/10.17925/ee.2021.17.1.12
  14. Defining and Classifying New Subgroups of Diabetes vol.72, pp.1, 2021, https://doi.org/10.1146/annurev-med-050219-034524
  15. Treating latent autoimmune diabetes in adults in the era of cardiovascular outcomes trials: Old dog should learn new tricks vol.38, pp.3, 2018, https://doi.org/10.1111/dme.14496
  16. The role of autoimmunity in the pathophysiology of type 2 diabetes: Looking at the other side of the moon vol.22, pp.8, 2018, https://doi.org/10.1111/obr.13231
  17. Antioxidant, Anti-Inflammatory, and Immunomodulatory Properties of Tea-The Positive Impact of Tea Consumption on Patients with Autoimmune Diabetes vol.13, pp.11, 2018, https://doi.org/10.3390/nu13113972
  18. Neutrophils and their role in the aetiopathogenesis of type 1 and type 2 diabetes vol.38, pp.1, 2018, https://doi.org/10.1002/dmrr.3483